SynBiotic SE (DUSE:SBX)
2.495
0.00 (0.00%)
At close: Jan 26, 2026
SynBiotic SE Revenue
In the year 2023, SynBiotic SE had annual revenue of 3.86M EUR, down -52.71%. SynBiotic SE had revenue of 3.55M in the quarter ending June 30, 2024.
Revenue
3.86M
Revenue Growth
-52.71%
P/S Ratio
4.41
Revenue / Employee
70.21K
Employees
55
Market Cap
17.02M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3.86M | -4.30M | -52.71% |
| Dec 31, 2022 | 8.17M | -898.09K | -9.91% |
| Dec 31, 2021 | 9.06M | 3.59M | 65.63% |
| Dec 31, 2020 | 5.47M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcandor AG | 20.22B |
| RheinLand Holding AG | 671.55M |
| Schulte-Schlagbaum AG | 57.38M |
| Calvert International AG | 3.41M |
| RM Rheiner Management AG | 1.06M |
| SCHNIGGE Capital Markets SE | 525.28K |
| Murphy & Spitz Green Capital Aktiengesellschaft | 344.44K |
| Advanced Bitcoin Technologies AG | 306.71K |
SynBiotic SE News
- 16 days ago - EQS-News: Global momentum in the cannabis market: New signals from the U.S. strengthen long-term prospects for Europe and SYNBIOTIC - Wallstreet:Online
- 7 weeks ago - Additional capital to support strategic realignment; chg. PT - Wallstreet:Online
- 7 weeks ago - CANSOUL Invests Strategically in SynBiotic: Stake Acquisition - Wallstreet:Online
- 7 weeks ago - EQS-News: Strategic Investment: CANSOUL acquires stake in SYNBIOTIC - Wallstreet:Online
- 2 months ago - EQS-News: SYNBIOTIC strengthens its presence at international events and monitors advances in cannabis research - Wallstreet:Online
- 3 months ago - EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate - Wallstreet:Online
- 3 months ago - Temporary headwinds from regulatory uncertainty; chg. est. - Wallstreet:Online
- 4 months ago - EQS-News: Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals - Wallstreet:Online